 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Lunit, a medical artificial intelligence (AI) company, will raise funds to strengthen research and development (R&D) through a paid-in capital increase of KRW 200 billion.
LUNIT announced on the 23rd that it has decided to increase its capital by 201.872 billion won. The paid-in capital increase method is a general public offering of disqualified shares after shareholder allocation.
As a result, Lunit will issue 1,857,150 new shares at 108,700 won per share. The price of new shares will change depending on the first issuance price and the final issuance price in the future. 0.14999995 shares per share will be allocated to existing shareholders.
In addition, it was decided to carry out a one-on-one free capital increase immediately after the paid-in capital increase. New shares issued as paid-in capital increase will also automatically participate in the free capital increase, resulting in the right to receive new shares without certificates.
In the field of Lunit Insight's new product development, funding will be used for the purchase and management of data sets for new modal and carcinoma expansion and clinical research.
It will also push for new businesses related to multi-body data extraction and AI-based medical data development and analysis platforms. To this end, if a positive result is derived using the Lunitscope among the candidate materials for new drug development, it is licensed. It plans to materialize a business model that develops it directly and connects it to commercialization or licenses it to large pharmaceutical companies.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
